Drug intelligence / Profile preview

VI-1121

Development stage: Phase 2
Lead developer: VIVUS LLC
Modality: Small Molecules

Overview

VI-1121 is a small molecule drug developed by VIVUS for the treatment of Alzheimer's disease. It was investigated as an adjunctive therapy in patients with Alzheimer's disease whose condition was worsening despite current standard treatments. The compound reached phase II clinical trials but development was discontinued after completion of these studies. The precise mechanism of action and molecular target for VI-1121 have not been publicly disclosed, and it is classified broadly as an antidementia agent[1][2][4][5].

Other names: VI 1121VI1121VI-1121

Beyond the preview

Go deeper on VI-1121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VI-1121.

Explore the full profile